Mutation burden and treatment response in spliceosome-mutated and wild-type cohorts. (A) Median mutation burden in patients with SF3B1, SRSF2, and U2AF1 mutations and in patients with vs without spliceosome mutations. (B) Composite CR rates in wild-type and spliceosome cohorts, and by individual spliceosome mutation.